[go: up one dir, main page]

IL245125B - Immediate release abuse-deterrent granulated dosage forms - Google Patents

Immediate release abuse-deterrent granulated dosage forms

Info

Publication number
IL245125B
IL245125B IL245125A IL24512516A IL245125B IL 245125 B IL245125 B IL 245125B IL 245125 A IL245125 A IL 245125A IL 24512516 A IL24512516 A IL 24512516A IL 245125 B IL245125 B IL 245125B
Authority
IL
Israel
Prior art keywords
dosage forms
immediate release
release abuse
deterrent
granulated dosage
Prior art date
Application number
IL245125A
Other languages
Hebrew (he)
Other versions
IL245125A0 (en
Original Assignee
Cima Labs Inc
Clexio Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2014/047014 external-priority patent/WO2015065547A1/en
Application filed by Cima Labs Inc, Clexio Biosciences Ltd filed Critical Cima Labs Inc
Publication of IL245125A0 publication Critical patent/IL245125A0/en
Publication of IL245125B publication Critical patent/IL245125B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL245125A 2013-10-31 2016-04-14 Immediate release abuse-deterrent granulated dosage forms IL245125B (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361898207P 2013-10-31 2013-10-31
PCT/US2014/047014 WO2015065547A1 (en) 2013-10-31 2014-07-17 Immediate release abuse-deterrent granulated dosage forms
US14/333,986 US20150118300A1 (en) 2013-10-31 2014-07-17 Immediate Release Abuse-Deterrent Granulated Dosage Forms
PCT/US2014/054061 WO2015065586A1 (en) 2013-10-31 2014-09-04 Immediate release abuse-deterrent granulated dosage forms
US14/477,354 US20150118301A1 (en) 2013-10-31 2014-09-04 Immediate Release Abuse-Deterrent Granulated Dosage Forms
US14/484,793 US20150118295A1 (en) 2013-10-31 2014-09-12 Immediate Release Abuse-Deterrent Granulated Dosage Forms
PCT/US2014/062887 WO2015066172A1 (en) 2013-10-31 2014-10-29 Immediate release abuse-deterrent granulated dosage forms

Publications (2)

Publication Number Publication Date
IL245125A0 IL245125A0 (en) 2016-06-30
IL245125B true IL245125B (en) 2021-06-30

Family

ID=53005066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL245125A IL245125B (en) 2013-10-31 2016-04-14 Immediate release abuse-deterrent granulated dosage forms

Country Status (5)

Country Link
EP (1) EP3062778A4 (en)
CA (1) CA2900858C (en)
EA (1) EA032013B1 (en)
IL (1) IL245125B (en)
WO (1) WO2015066172A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
CA2970065A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
WO2018044895A1 (en) * 2016-08-29 2018-03-08 Cima Labs Inc. Immediate release dosage forms with abuse deterrence and alcohol resistance
JP2021529732A (en) 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー. How to treat major depressive disorder
JP2022504036A (en) 2018-10-05 2022-01-13 クレキシオ バイオサイエンシーズ エルティーディー. Esketamine dosing regimen for the treatment of major depressive disorder
EP3965733A4 (en) 2019-05-07 2023-01-11 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regimen with escitamine for the treatment of clinical depression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
PT1276470E (en) * 2000-04-20 2007-08-13 Novartis Ag Taste masking coating composition
ES2361148T3 (en) * 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. DOSAGE FORM OF ABUSE RESISTANT CONTROLLED OPIOID OPTION.
US9125833B2 (en) * 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
US20090022798A1 (en) * 2007-07-20 2009-01-22 Abbott Gmbh & Co. Kg Formulations of nonopioid and confined opioid analgesics
CN105534936B (en) * 2007-08-13 2020-07-31 Ohemo 生命科学股份有限公司 Abuse resistant drugs, methods of use and methods of preparation
WO2010044842A1 (en) * 2008-10-16 2010-04-22 University Of Tennessee Research Foundation Tamper resistant oral dosage forms containing an embolizing agent
WO2012061779A1 (en) * 2010-11-04 2012-05-10 Abbott Gmbh & Co. Kg Drug formulations
JP6199321B2 (en) * 2012-03-02 2017-09-20 ローズ ファーマシューティカルズ エル.ピー. Improper use resistant immediate release formulation

Also Published As

Publication number Publication date
EA032013B1 (en) 2019-03-29
EA201690874A1 (en) 2016-08-31
EP3062778A1 (en) 2016-09-07
CA2900858C (en) 2017-05-02
CA2900858A1 (en) 2015-05-07
IL245125A0 (en) 2016-06-30
WO2015066172A1 (en) 2015-05-07
EP3062778A4 (en) 2017-07-19

Similar Documents

Publication Publication Date Title
HK1223856A1 (en) Immediate release abuse-deterrent granulated dosage forms
IL252708A0 (en) Immediate release abuse-deterrent granulated dosage forms
GB201322602D0 (en) Pharmaceutical compounds
GB201309085D0 (en) Compounds
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201306610D0 (en) Pharmaceutical compounds
GB201309508D0 (en) Compounds
IL245125A0 (en) Immediate release abuse-deterrent granulated dosage forms
IL245124A0 (en) Abuse-deterrent dosage forms
ZA201602047B (en) Pharmaceutical compounds
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
HK1223012A1 (en) Antiemetic extended release solid dosage forms
IL241350A0 (en) Sovaprevir tablets
GB201312386D0 (en) Pharmaceutical compounds
EP2948457A4 (en) Compounds
GB201306794D0 (en) Compounds
GB201413253D0 (en) Solid dosage form
GB201302219D0 (en) Contraceptive compounds
GB201317166D0 (en) Pharmaceutical compounds
GB201316791D0 (en) Pharmaceutical Compounds
GB201316780D0 (en) Pharmaceutical compounds
GB201315734D0 (en) Pharmaceutical compounds
GB201315733D0 (en) Pharmaceutical compounds
GB201312464D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
FF Patent granted